Biodexa Pharmaceuticals Plc Nasdaq

BDRX

US59564R8079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-16 pm EST			5-day change	1st Jan Change
6.500 ^USD	+35.98%		+59.71%	-83.95%

Dec. 16	European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	MT
Dec. 16	Top Premarket Gainers	MT

Biodexa Pharmaceuticals to Buy License to Commercialize Tolimidone for Diabetes; Shares Soar

Published on 11/27/2023 at 10:54 am EST - Modified on 11/27/2023 at 10:55 am EST

MT Newswires

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Biodexa Pharmaceuticals Plc

Dec. 16	European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	MT
Dec. 16	Top Premarket Gainers	MT
Dec. 15	European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	MT
Dec. 15	Top Premarket Gainers	MT
Dec. 12	European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading; Shares Still Up This Week	MT
Dec. 11	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
Dec. 10	European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	MT
Dec. 10	Top Premarket Gainers	MT
Dec. 09	European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
Dec. 08	European Equities Traded in the US as ADRs Little Changed in Monday Trading	MT
Dec. 08	Top Premarket Gainers	MT
Dec. 04	European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	MT
Dec. 03	European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading	MT
Nov. 25	European Equities Traded in the US as American Depositary Receipts Turn Sharply Higher in Tuesday Trading	MT
Nov. 24	European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading	MT
Nov. 24	Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP	CI
Nov. 20	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
Nov. 18	European Equities Traded in the US as American Depositary Receipts Down Sharply in Friday Trading	MT
Nov. 17	European Equities Traded in the US as American Depositary Receipts Slightly Lower in Monday Trading	MT
Nov. 14	European Equities Traded in the US as American Depositary Receipts Decline in Friday Trading	MT
Nov. 13	European Equities Traded in the US as American Depositary Receipts Slightly Higher in Thursday Trading	MT
Nov. 10	European Equities Traded in the US as American Depositary Receipts Start Week Trending Higher in Monday Trading	MT
Nov. 07	European Equities Traded in the US as American Depositary Receipts Edge Lower in Friday Trading; Down Modestly for Week	MT
Nov. 04	European Equities Traded in the US as American Depositary Receipts Track Lower in Tuesday Trading	MT
Nov. 03	European Equities Traded in the US as American Depositary Receipts Little Changed in Monday Trading	MT

Chart Biodexa Pharmaceuticals Plc

Duration

Period

BDRX: Dynamic Chart

Biodexa Pharmaceuticals PLC is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is developing a pipeline of products for the treatment of diseases with unmet medical needs. Its technologies include Biodexa Pharmaceuticals Q-Sphera, MidaCore and MidaSolve. The Q-Sphera technology focuses on long-acting injectables using proprietary three-dimensional (3D) printing technology that encapsulates medicines into bioresorbable polymer microspheres with precision characteristics. The MidaCore technology platform uses ultra-small gold nanoparticle (GNP) drug conjugates. The MidaSolve Nano Inclusion technology solubilizes molecules that have minimal solubility biological potential of Hydrogen (pH), extending available routes of administration, including direct-to-tumor delivery. Its pipeline includes MTX110, MTD201, MTD211 (Schizophrenia, MDD), MTX223, and MTD217.

Employees

Sector

Biotechnology & Medical Research

Calendar

Apr. 23 - Q4 2025 Earnings Release (Projected)

More about the company